Patents by Inventor Mark Robert Hurle

Mark Robert Hurle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human Tumor Necrosis Factor Receptor-Like 2
    Publication number: 20090131319
    Abstract: The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding a human TR2 receptor and two splice variants thereof. TR2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR2 receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of TR2 receptors. Further provided are therapeutic methods for treating disease states related to aberrant proliferation and differentiation of cells which express the TR2 receptors.
    Type: Application
    Filed: September 23, 2008
    Publication date: May 21, 2009
    Applicants: Human Genome Sciences, Inc., SmithKline Beecham Corp.
    Inventors: Jian Ni, Craig A. Rosen, Reiner L. Gentz, Sally Doreen Patricia Lyn, Mark Robert Hurle
  • Human tumor necrosis factor receptor-like 2
    Patent number: 7446169
    Abstract: The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding a human TR2 receptor and two splice variants thereof. TR2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR2 receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of TR2 receptors. Further provided are therapeutic methods for treating disease states related to aberrant proliferation and differentiation of cells which express the TR2 receptors.
    Type: Grant
    Filed: June 29, 1999
    Date of Patent: November 4, 2008
    Assignees: Human Genome Sciences, Inc., SmithKline Beecham Corporation
    Inventors: Jian Ni, Craig A. Rosen, Reiner L. Gentz, Sally Doreen Patricia Lyn, Mark Robert Hurle
  • PIGR-1, a member of immunoglobulin gene superfamily
    Patent number: 6232441
    Abstract: PIGR-1 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing PIGR-1 polypeptides and polynucleotides in the design of protocols for the treatment of rheumatoid arthritis (RA), multiple sclerosis (MS), psoriasis, systemic lupus erythematosus (SLE) and inflammatory bowel disease (IBD), among others and diagnostic assays for such conditions.
    Type: Grant
    Filed: April 28, 1999
    Date of Patent: May 15, 2001
    Assignee: SmithKline Beecham Corporation
    Inventors: Shujian Wu, Raymond W Sweet, Alemseged Truneh, Mark Robert Hurle
  • Human requiem
    Patent number: 6207803
    Abstract: Human REQUIEM polypeptides and DNA (RNA) encoding such REQUIEM and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such REQUIEM for the treatment of a susceptibility to viral infection, tumorogenesis and to diseases and defects in the control of embryogenesis and tissue homeostasis, and the nucleic acid sequences described above may be employed in an assay for ascertaining such susceptibility.
    Type: Grant
    Filed: January 19, 1999
    Date of Patent: March 27, 2001
    Assignee: SmithKline Beecham Corporation
    Inventors: Mitchell S Gross, Mark Robert Hurle, Kristine Kay Kikly
  • PIGR-1, a member of immunoglobulin gene superfamily
    Patent number: 6020161
    Abstract: PIGR-1 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing PIGR-1 polypeptides and polynucleotides in the design of protocols for the treatment of rheumatoid arthritis (RA), multiple sclerosis (MS), psoriasis, systemic lupus erythematosus (SLE) and inflammatory bowel disease (IBD), among others and diagnostic assays for such conditions.
    Type: Grant
    Filed: October 22, 1997
    Date of Patent: February 1, 2000
    Assignee: SmithKline Beecham Corporation
    Inventors: Shujian Wu, Raymond W Sweet, Alemseged Truneh, Mark Robert Hurle
  • Human requiem
    Patent number: 5919660
    Abstract: Human REQUIEM polypeptides and DNA (RNA) encoding such REQUIEM and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such REQUIEM for the treatment of a susceptibility to viral infection, tumorogenesis and to diseases and defects in the control embryogenesis and tissue homeostasis, and the nucleic acid sequences described above may be employed in an assay for ascertaining such susceptibility.
    Type: Grant
    Filed: June 24, 1997
    Date of Patent: July 6, 1999
    Assignee: SmithKline Beecham Corporation
    Inventors: Mitchell S Gross, Mark Robert Hurle, Kristine Kay Kikly
  • Smooth muscle cell-derived migration factor
    Patent number: 5916758
    Abstract: Isolated nucleic acid encoding human smooth muscle cell-derived migration factor, protein obtainable from the nucleic acid, recombinant host cells transformed with the nucleic acid and use of the protein and nucleic acid sequence are disclosed.
    Type: Grant
    Filed: April 23, 1997
    Date of Patent: June 29, 1999
    Inventors: Mark Robert Hurle, Peter Colon McDonnell, Dean Edward McNulty, Craig Alan Rosen, Ivo Rogulia Siemens, Peter Ronald Young, Tian-Li Yue